BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 37563671)

  • 41. Regulation of gonadotropin secretion: implications for polycystic ovary syndrome.
    McCartney CR; Eagleson CA; Marshall JC
    Semin Reprod Med; 2002 Nov; 20(4):317-26. PubMed ID: 12536355
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Polymorphisms of transcription factor-7-like 2 (TCF7L2) gene in Tunisian women with polycystic ovary syndrome (PCOS).
    Ben-Salem A; Ajina M; Suissi M; Daher HS; Almawi WY; Mahjoub T
    Gene; 2014 Jan; 533(2):554-7. PubMed ID: 24157263
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Overactivation of GnRH neurons is sufficient to trigger polycystic ovary syndrome-like traits in female mice.
    Silva MSB; Decoster L; Delpouve G; Lhomme T; Ternier G; Prevot V; Giacobini P
    EBioMedicine; 2023 Nov; 97():104850. PubMed ID: 37898094
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The role of polymorphism in various potential genes on polycystic ovary syndrome susceptibility and pathogenesis.
    Chaudhary H; Patel J; Jain NK; Joshi R
    J Ovarian Res; 2021 Sep; 14(1):125. PubMed ID: 34563259
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Circulating leptin concentration, LEP gene variants and haplotypes, and polycystic ovary syndrome in Bahraini and Tunisian Arab women.
    Dallel M; Sghaier I; Finan RR; Douma Z; Hachani F; Letaifa DB; Mahjoub T; Almawi WY
    Gene; 2019 Apr; 694():19-25. PubMed ID: 30721746
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacogenetics of D2 dopamine receptor gene in prolactin-secreting pituitary adenomas.
    Filopanti M; Lania AG; Spada A
    Expert Opin Drug Metab Toxicol; 2010 Jan; 6(1):43-53. PubMed ID: 19929252
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prepubertal Development of GABAergic Transmission to Gonadotropin-Releasing Hormone (GnRH) Neurons and Postsynaptic Response Are Altered by Prenatal Androgenization.
    Berg T; Silveira MA; Moenter SM
    J Neurosci; 2018 Feb; 38(9):2283-2293. PubMed ID: 29374136
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evidence of altered dopaminergic modulation of prolactin and thyrotropin secretion in patients with polycystic ovary syndrome.
    Velardo A; Pantaleoni M; Zironi C; Zizzo G; Marrama P
    Horm Res; 1991; 35(1):4-7. PubMed ID: 1916652
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pituitary function is altered during the same cycle in women with polycystic ovary syndrome treated with continuous or cyclic oral contraceptives or a gonadotropin-releasing hormone agonist.
    Ruchhoft EA; Elkind-Hirsch KE; Malinak R
    Fertil Steril; 1996 Jul; 66(1):54-60. PubMed ID: 8752611
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Gonadotrophin-releasing hormone receptor autoantibodies induce polycystic ovary syndrome-like features in a rat model.
    Li H; Guo Y; Zhang G; Deng J; Fischer H; Craig LB; Yu X; Kem DC
    Exp Physiol; 2021 Apr; 106(4):902-912. PubMed ID: 33576068
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prevalence of polycystic ovarian changes and polycystic ovary syndrome in premenopausal women with treated type 2 diabetes mellitus.
    Kelestimur F; Unluhizarci K; Baybuga H; Atmaca H; Bayram F; Sahin Y
    Fertil Steril; 2006 Aug; 86(2):405-10. PubMed ID: 16762349
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of apoC1 genotypes on the hormonal levels, metabolic profile and PAF-AH activity in Chinese women with polycystic ovary syndrome.
    Zhang R; Liu Q; Liu H; Bai H; Zhang Y; Guan L; Fan P
    Lipids Health Dis; 2018 Apr; 17(1):77. PubMed ID: 29636060
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Elevated prenatal anti-Müllerian hormone reprograms the fetus and induces polycystic ovary syndrome in adulthood.
    Tata B; Mimouni NEH; Barbotin AL; Malone SA; Loyens A; Pigny P; Dewailly D; Catteau-Jonard S; Sundström-Poromaa I; Piltonen TT; Dal Bello F; Medana C; Prevot V; Clasadonte J; Giacobini P
    Nat Med; 2018 Jun; 24(6):834-846. PubMed ID: 29760445
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Association of MEP1A gene variants with insulin metabolism in central European women with polycystic ovary syndrome.
    Lam UD; Lerchbaum E; Schweighofer N; Trummer O; Eberhard K; Genser B; Pieber TR; Obermayer-Pietsch B
    Gene; 2014 Mar; 537(2):245-52. PubMed ID: 24388959
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Estrogen receptor αlpha gene (ESR1) PvuII and XbaI polymorphisms are associated to metabolic and proinflammatory factors in polycystic ovary syndrome.
    Silva FS; Sóter MO; Sales MF; Candido AL; Reis FM; Silva IF; Sousa MO; Ferreira CN; Gomes KB
    Gene; 2015 Apr; 560(1):44-9. PubMed ID: 25617525
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Specific factors predict the response to pulsatile gonadotropin-releasing hormone therapy in polycystic ovarian syndrome.
    Gill S; Taylor AE; Martin KA; Welt CK; Adams JM; Hall JE
    J Clin Endocrinol Metab; 2001 Jun; 86(6):2428-36. PubMed ID: 11397835
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Steroidogenic regulatory factor FOS is underexpressed in polycystic ovary syndrome (PCOS) adipose tissue and genetically associated with PCOS susceptibility.
    Jones MR; Chazenbalk G; Xu N; Chua AK; Eigler T; Mengesha E; Chen YH; Lee JM; Pall M; Li X; Chen YD; Taylor KD; Mathur R; Krauss RM; Rotter JI; Legro RS; Azziz R; Goodarzi MO
    J Clin Endocrinol Metab; 2012 Sep; 97(9):E1750-7. PubMed ID: 22723319
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Potential for NPY receptor-related therapies for polycystic ovary syndrome: an updated review.
    Chen WH; Shi YC; Huang QY; Chen JM; Wang ZY; Lin S; Shi QY
    Hormones (Athens); 2023 Sep; 22(3):441-451. PubMed ID: 37452264
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ovarian 17-hydroxyprogesterone hyperresponsiveness to gonadotropin-releasing hormone (GnRH) agonist challenge in women with polycystic ovary syndrome is not mediated by luteinizing hormone hypersecretion: evidence from GnRH agonist and human chorionic gonadotropin stimulation testing.
    Ibañez L; Hall JE; Potau N; Carrascosa A; Prat N; Taylor AE
    J Clin Endocrinol Metab; 1996 Nov; 81(11):4103-7. PubMed ID: 8923867
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cabergoline and prolactinomas: lack of association between DRD2 polymorphisms and response to treatment.
    Bueno C; Trarbach EB; Bronstein MD; Glezer A
    Pituitary; 2017 Jun; 20(3):295-300. PubMed ID: 27848079
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.